PT - JOURNAL ARTICLE AU - Stephen A. Rettie AU - Katelyn V. Campbell AU - Asim K. Bera AU - Alex Kang AU - Simon Kozlov AU - Joshmyn De La Cruz AU - Victor Adebomi AU - Guangfeng Zhou AU - Frank DiMaio AU - Sergey Ovchinnikov AU - Gaurav Bhardwaj TI - Cyclic peptide structure prediction and design using AlphaFold AID - 10.1101/2023.02.25.529956 DP - 2023 Jan 01 TA - bioRxiv PG - 2023.02.25.529956 4099 - http://biorxiv.org/content/early/2023/02/26/2023.02.25.529956.short 4100 - http://biorxiv.org/content/early/2023/02/26/2023.02.25.529956.full AB - Deep learning networks offer considerable opportunities for accurate structure prediction and design of biomolecules. While cyclic peptides have gained significant traction as a therapeutic modality, developing deep learning methods for designing such peptides has been slow, mostly due to the small number of available structures for molecules in this size range. Here, we report approaches to modify the AlphaFold network for accurate structure prediction and design of cyclic peptides. Our results show this approach can accurately predict the structures of native cyclic peptides from a single sequence, with 36 out of 49 cases predicted with high confidence (pLDDT > 0.85) matching the native structure with root mean squared deviation (RMSD) less than 1.5 Å. Further extending our approach, we describe computational methods for designing sequences of peptide backbones generated by other backbone sampling methods and for de novo design of new macrocyclic peptides. We extensively sampled the structural diversity of cyclic peptides between 7–13 amino acids, and identified around 10,000 unique design candidates predicted to fold into the designed structures with high confidence. X-ray crystal structures for seven sequences with diverse sizes and structures designed by our approach match very closely with the design models (root mean squared deviation < 1.0 Å), highlighting the atomic level accuracy in our approach. The computational methods and scaffolds developed here provide the basis for custom-designing peptides for targeted therapeutic applications.Competing Interest StatementGB is a co-founder, shareholder, and advisor for Vilya, a biotech company in Seattle, WA, USA.